BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock Overview
USA - NASDAQ:BBOT - US1079241022 - Common Stock
BBOT Key Statistics, Chart & Performance
The current stock price of BBOT is 11.02 USD. In the past month the price decreased by -2%.
BBOT Latest News, Press Relases and Analysis
BBOT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.85 | 408.76B | ||
| AMGN | AMGEN INC | 13.81 | 162.12B | ||
| GILD | GILEAD SCIENCES INC | 16.03 | 153.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.16 | 109.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.69 | 61.40B | ||
| ARGX | ARGENX SE - ADR | 90.64 | 51.39B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.70B | ||
| NTRA | NATERA INC | N/A | 25.65B | ||
| BIIB | BIOGEN INC | 9.13 | 21.44B |
Related stock screener links
About BBOT
Company Profile
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
Company Info
BRIDGEBIO ONCOLOGY THERAPEUT
256 E. Grand Avenue, Suite 104
South San Francisco CALIFORNIA US
Employees: 0
Phone: 18577020377
BRIDGEBIO ONCOLOGY THERAPEUT / BBOT FAQ
What is the stock price of BRIDGEBIO ONCOLOGY THERAPEUT today?
The current stock price of BBOT is 11.02 USD. The price decreased by -2.04% in the last trading session.
What is the ticker symbol for BRIDGEBIO ONCOLOGY THERAPEUT stock?
The exchange symbol of BRIDGEBIO ONCOLOGY THERAPEUT is BBOT and it is listed on the Nasdaq exchange.
On which exchange is BBOT stock listed?
BBOT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BRIDGEBIO ONCOLOGY THERAPEUT stock?
12 analysts have analysed BBOT and the average price target is 24.68 USD. This implies a price increase of 123.99% is expected in the next year compared to the current price of 11.02. Check the BRIDGEBIO ONCOLOGY THERAPEUT stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BRIDGEBIO ONCOLOGY THERAPEUT worth?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) has a market capitalization of 872.78M USD. This makes BBOT a Small Cap stock.
How many employees does BRIDGEBIO ONCOLOGY THERAPEUT have?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) currently has 0 employees.
What are the support and resistance levels for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) has a support level at 11.01 and a resistance level at 12.37. Check the full technical report for a detailed analysis of BBOT support and resistance levels.
Should I buy BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BBOT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BBOT, evaluating the profitability, health, valuation and growth aspects
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Sales and EPS estimates to see what analysts future expectations are.
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock Chart to make your own analysis
- BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Latest news and press-releases to stay up to date.
Does BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock pay dividends?
BBOT does not pay a dividend.
What is the Price/Earnings (PE) ratio of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT)?
The PE ratio for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 55.1. This is based on the reported non-GAAP earnings per share of 0.2 and the current share price of 11.02 USD. Check the full fundamental report for a full analysis of the valuation metrics for BBOT.
What is the Short Interest ratio of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?
The outstanding short interest for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 0.13% of its float. Check the ownership tab for more information on the BBOT short interest.
BBOT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BBOT.
BBOT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BBOT. The financial health of BBOT is average, but there are quite some concerns on its profitability.
BBOT Financial Highlights
Over the last trailing twelve months BBOT reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 17.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 2.39% | ||
| ROE | 2.49% | ||
| Debt/Equity | 0 |
BBOT Forecast & Estimates
12 analysts have analysed BBOT and the average price target is 24.68 USD. This implies a price increase of 123.99% is expected in the next year compared to the current price of 11.02.